The scientific focus adapted
to express the optimum potential
of your molecule

Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Physiogenex to present at the NASH-TAG 2019

News detail

Return to all news & events

01/02/2019 Physiogenex to present at the NASH-TAG 2019

Physiogenex will present at the NASH-TAG 2019 in Park City, UT, USA, January 3rd-5th, 2019.

Dr. François Briand, Director of Research and Business Development, will be presenting one poster dealing with Physiogenex NASH animal models, and a second poster dealing with the measurement of alpha-SMA protein levels in NASH/fibrosis models, using a HTRF assay kit developed by Cisbio.

If you wish to set-up an appointment with Dr. François Briand to discuss about your preclinical NASH projects, please contact us.

About Physiogenex

Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications. We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We focus on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.

Please visit our website for more information